---
layout: default
title: Amcinonide
description: "Amcinonide çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚ä¸­ç­‰è­‰æ“šç­‰ç´š L3ï¼ŒåŒ…å« 8 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: ä¸­è­‰æ“šç­‰ç´š (L3-L4)
nav_order: 21
evidence_level: L4
indication_count: 8
---

# Amcinonide

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L3</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>8</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Amcinonideï¼šå¾ç•°ä½æ€§çš®è†šç‚åˆ°çš®è†šç‚

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Amcinonide å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Amcinonide åŸæœ¬ç”¨æ–¼æ²»ç™‚æ€¥æ…¢æ€§çš®è†šç—…å¦‚ç•°ä½æ€§çš®è†šç‚ã€æ¥è§¸æ€§çš®è†šç‚ã€ç‰›çš®ç™¬ç­‰ã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**çš®è†šç‚ (dermatitis)** æœ‰æ•ˆï¼Œ
ç›®å‰æœ‰ **20 ç¯‡æ–‡ç»**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | ç•°ä½æ€§çš®è†šç‚ã€æ¥è§¸æ€§çš®è†šç‚ã€æ¿•ç–¹ã€ç‰›çš®ç™¬ã€ç¥ç¶“æ€§çš®è†šç‚ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | lichen diseaseã€seborrheic dermatitisã€seborrheic keratosisã€vulvar inverted follicular keratosisã€annular atrophic lichen planusã€lichen planus pigmentosusã€hypertrophic lichen planusã€primary cutaneous T-cell non-Hodgkin lymphoma |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.30% |
| è­‰æ“šç­‰ç´š | L3 |
| å°ç£ä¸Šå¸‚ | æœ‰ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 6 å¼µï¼ˆå¤šæ•¸å·²è¨»éŠ·ï¼‰ |
| å»ºè­°æ±ºç­– | Already Approved (åŸé©æ‡‰ç—‡ç¯„åœå…§) |





## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. vulvar inverted follicular keratosis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.82%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p>Amcinonide æ˜¯é«˜æ•ˆåƒ¹å±€éƒ¨é¡å›ºé†‡ï¼Œå±¬æ–¼å‰¯è…çš®è³ªè·çˆ¾è’™é¡è—¥ç‰©ã€‚å…¶ä½œç”¨æ©Ÿè½‰åŒ…æ‹¬ï¼š</p>

<ol>
<li><strong>æŠ—ç™¼ç‚ä½œç”¨</strong>ï¼šæŠ‘åˆ¶ç™¼ç‚ä»‹è³ªçš„é‡‹æ”¾ï¼Œæ¸›å°‘è¡€ç®¡æ“´å¼µèˆ‡æ°´è…«</li>
<li><strong>æŠ—éæ•ä½œç”¨</strong>ï¼šç©©å®šè‚¥å¤§ç´°èƒï¼Œæ¸›å°‘çµ„ç¹”èƒºé‡‹æ”¾</li>
<li><strong>å…ç–«èª¿ç¯€</strong>ï¼šæŠ‘åˆ¶å…ç–«ç´°èƒçš„æ´»åŒ–èˆ‡é·ç§»</li>

</ol>
<p>é æ¸¬é©æ‡‰ç—‡ã€Œçš®è†šç‚ã€å¯¦éš›ä¸Šå·²åŒ…å«åœ¨åŸé©æ‡‰ç—‡ç¯„åœå…§ï¼ˆå¦‚ç•°ä½æ€§çš®è†šç‚ã€æ¥è§¸æ€§çš®è†šç‚çš†å±¬çš®è†šç‚ï¼‰ï¼Œæ­¤é æ¸¬å°è­‰äº†æ¨¡å‹å°è©²è—¥ç‰©é©æ‡‰ç—‡çš„æ­£ç¢ºè­˜åˆ¥ã€‚</p>

<h3>è‡¨åºŠè©¦é©—</h3>

<p>ç›®å‰ç„¡é‡å°æ­¤ç‰¹å®šé©æ‡‰ç—‡çš„è‡¨åºŠè©¦é©—ç™»è¨˜ã€‚</p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. annular atrophic lichen planus</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.73%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. lichen planus pigmentosus</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.73%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. hypertrophic lichen planus</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.73%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. lichen planus pemphigoides</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.64%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. primary cutaneous B-cell lymphoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.42%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. dermatitis</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.30%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/6383735/" target="_blank">6383735</a></td><td>1984</td><td>Article</td><td>Cutis</td><td>A comparative study of amcinonide and halcinonide in the treatment of eczematous...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/7030645/" target="_blank">7030645</a></td><td>1981</td><td>Article</td><td>Cutis</td><td>A controlled comparison of amcinonide cream 0.1 percent and halcinonide cream 0....</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/3816214/" target="_blank">3816214</a></td><td>1987</td><td>Article</td><td>Contact dermatitis</td><td>Contact dermatitis from amcinonide.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/3160532/" target="_blank">3160532</a></td><td>1985</td><td>Article</td><td>Contact dermatitis</td><td>Allergic contact dermatitis from amcinonide.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/820519/" target="_blank">820519</a></td><td>1976</td><td>Article</td><td>Current therapeutic research, </td><td>A double-blind comparative study between amcinonide and betamethasone valerate i...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/391500/" target="_blank">391500</a></td><td>1979</td><td>Article</td><td>Cutis</td><td>Management of eczematous dermatitis with amcinonide or betamethasone valerate. A...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2144811/" target="_blank">2144811</a></td><td>1990</td><td>Article</td><td>Contact dermatitis</td><td>Allergic contact dermatitis due to amcinonide.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32555122/" target="_blank">32555122</a></td><td>2020</td><td>Article</td><td>The Medical letter on drugs an</td><td>Drugs for atopic dermatitis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2964991/" target="_blank">2964991</a></td><td>1988</td><td>Article</td><td>Contact dermatitis</td><td>Contact dermatitis due to amcinonide.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/6233341/" target="_blank">6233341</a></td><td>1984</td><td>Article</td><td>Journal of the American Academ</td><td>Contact sensitivity to topical corticosteroids.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2530056/" target="_blank">2530056</a></td><td>1989</td><td>Article</td><td>Contact dermatitis</td><td>Allergic contact dermatitis from topical corticosteroids.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/11683835/" target="_blank">11683835</a></td><td>2001</td><td>Article</td><td>Contact dermatitis</td><td>Exacerbation of allergic contact dermatitis from amcinonide triggered by patch t...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/1834432/" target="_blank">1834432</a></td><td>1991</td><td>Article</td><td>Contact dermatitis</td><td>Contact allergies to topical corticosteroids: 10 cases of contact dermatitis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39652964/" target="_blank">39652964</a></td><td>2024</td><td>Article</td><td>Dermatology practical &amp; concep</td><td>Differential Diagnosis of Irritant Versus Allergic Contact Dermatitis Based on N...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/1831101/" target="_blank">1831101</a></td><td>1991</td><td>Article</td><td>Contact dermatitis</td><td>Contact dermatitis from budesonide in a nasal spray without cross-reactivity to ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/8462297/" target="_blank">8462297</a></td><td>1993</td><td>Article</td><td>Contact dermatitis</td><td>Contact allergies to topical corticosteroids.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2946521/" target="_blank">2946521</a></td><td>1986</td><td>Article</td><td>Contact dermatitis</td><td>Contact allergy to amcinonide.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/10894975/" target="_blank">10894975</a></td><td>2000</td><td>Article</td><td>Dermatology (Basel, Switzerlan</td><td>Delayed generalized allergic reactions to corticosteroids.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/7826093/" target="_blank">7826093</a></td><td>1995</td><td>Article</td><td>Archives of dermatology</td><td>Studies in patients with corticosteroid contact allergy. Understanding cross-rea...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/6488784/" target="_blank">6488784</a></td><td>1984</td><td>Article</td><td>Contact dermatitis</td><td>Allergy to 2 new corticoid molecules.</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. 2-hydroxyethyl methacrylate sensitization</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.00%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ | ç‹€æ…‹ |
|---------|------|------|-----------|------|
| è¡›ç½²è—¥è£½å­—ç¬¬027348è™Ÿ | é•·å®‰èˆ’æ·ä¹³è† | ä¹³è†åŠ‘ | çš®è†šç‚ã€æ¿•ç–¹ã€ç‰›çš®ç™¬ç­‰ | æœ‰æ•ˆ |
| è¡›ç½²è—¥è£½å­—ç¬¬023167è™Ÿ | è†šæ»‹ä¹³è† | ä¹³è†åŠ‘ | ç•°ä½æ€§çš®è†šç‚ã€æ¥è§¸æ€§çš®è†šç—… | å·²è¨»éŠ· |
| è¡›ç½²è—¥è£½å­—ç¬¬044950è™Ÿ | å®‰é©ä¹³è† | ä¹³è†åŠ‘ | æ€¥æ…¢æ€§çš®è†šç—… | å·²è¨»éŠ· |

å‚™è¨»ï¼šç›®å‰åƒ…ã€Œé•·å®‰èˆ’æ·ä¹³è†ã€è¨±å¯è­‰æœ‰æ•ˆï¼ˆè‡³2029å¹´ï¼‰ã€‚

## å®‰å…¨æ€§è€ƒé‡

- **è—¥ç‰©äº¤äº’ä½œç”¨**ï¼š
  - **è¼•å¾®äº¤äº’ä½œç”¨**ï¼šèˆ‡å¤šç¨®é™è¡€ç³–è—¥ç‰©ï¼ˆMetforminã€Glimepirideã€å„é¡èƒ°å³¶ç´ ç­‰ï¼‰ä½µç”¨å¯èƒ½å½±éŸ¿è¡€ç³–æ§åˆ¶
- **å±€éƒ¨ä½¿ç”¨æ³¨æ„äº‹é …**ï¼š
  - é•·æœŸä½¿ç”¨å¯èƒ½å°è‡´çš®è†šèç¸®ã€æ¯›ç´°è¡€ç®¡æ“´å¼µ
  - å¤§é¢ç©æˆ–å°é–‰å¼ä½¿ç”¨å¯èƒ½å¢åŠ å…¨èº«æ€§å¸æ”¶é¢¨éšª
- **éæ•åæ‡‰**ï¼šæ–‡ç»å ±å‘Šé¡¯ç¤ºéƒ¨åˆ†æ‚£è€…å° amcinonide ç”¢ç”Ÿæ¥è§¸æ€§çš®è†šç‚ï¼Œéœ€æ³¨æ„äº¤å‰éæ•


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**ç³–å°¿ç—…** ğŸŸ¡ Moderate
- æ‡‰é¿å…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚é¢¨éšªåŒ…æ‹¬ï¼šé«˜è¡€ç³–ã€‚ç‰¹åˆ¥æ³¨æ„æ—ç¾¤ï¼šå…’ç«¥ã€‚

**Diaper Rash** ğŸŸ¡ Moderate
- ä¸å»ºè­°ä½¿ç”¨æœ¬è—¥ç‰©ã€‚ç‰¹åˆ¥æ³¨æ„æ—ç¾¤ï¼šå…’ç«¥ã€‚

**Adrenocortical Hyperfunction** ğŸŸ¡ Moderate
- æ‡‰é¿å…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚ç‰¹åˆ¥æ³¨æ„æ—ç¾¤ï¼šå…’ç«¥ã€‚

**Infections** ğŸŸ¡ Moderate
- ä¸æ‡‰ä½¿ç”¨æœ¬è—¥ç‰©ã€‚é¢¨éšªåŒ…æ‹¬ï¼šæ„ŸæŸ“ã€‚ç‰¹åˆ¥æ³¨æ„æ—ç¾¤ï¼šå…’ç«¥ã€‚

**Toxic Optic Neuropathy** ğŸŸ¡ Moderate
- ç‰¹åˆ¥æ³¨æ„æ—ç¾¤ï¼šå…’ç«¥ã€‚

**ç³–å°¿ç—…** ğŸŸ¡ Moderate
- æ‡‰é¿å…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚é¢¨éšªåŒ…æ‹¬ï¼šé«˜è¡€ç³–ã€‚ç‰¹åˆ¥æ³¨æ„æ—ç¾¤ï¼šå…’ç«¥ã€‚

**Diaper Rash** ğŸŸ¡ Moderate
- ä¸å»ºè­°ä½¿ç”¨æœ¬è—¥ç‰©ã€‚ç‰¹åˆ¥æ³¨æ„æ—ç¾¤ï¼šå…’ç«¥ã€‚

**Adrenocortical Hyperfunction** ğŸŸ¡ Moderate
- æ‡‰é¿å…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚ç‰¹åˆ¥æ³¨æ„æ—ç¾¤ï¼šå…’ç«¥ã€‚

**Infections** ğŸŸ¡ Moderate
- ä¸æ‡‰ä½¿ç”¨æœ¬è—¥ç‰©ã€‚é¢¨éšªåŒ…æ‹¬ï¼šæ„ŸæŸ“ã€‚ç‰¹åˆ¥æ³¨æ„æ—ç¾¤ï¼šå…’ç«¥ã€‚

**Toxic Optic Neuropathy** ğŸŸ¡ Moderate
- ç‰¹åˆ¥æ³¨æ„æ—ç¾¤ï¼šå…’ç«¥ã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šAlready Approved (åŸé©æ‡‰ç—‡ç¯„åœå…§)**

**ç†ç”±ï¼š**
é æ¸¬é©æ‡‰ç—‡ã€Œçš®è†šç‚ã€å¯¦éš›ä¸Šå·²åŒ…å«åœ¨åŸæ ¸å‡†é©æ‡‰ç—‡ä¸­ã€‚Amcinonide ä½œç‚ºé«˜æ•ˆåƒ¹å±€éƒ¨é¡å›ºé†‡ï¼Œå°å„é¡çš®è†šç‚å‡æœ‰ç™‚æ•ˆã€‚æ­¤é æ¸¬é©—è­‰äº†æ¨¡å‹å°è—¥ç‰©-ç–¾ç—…é—œä¿‚çš„æ­£ç¢ºè­˜åˆ¥ã€‚

**è‡¨åºŠå»ºè­°ï¼š**
- ä¾æ“šçš®è†šç‚åš´é‡ç¨‹åº¦é¸æ“‡é©ç•¶æ•ˆåƒ¹çš„é¡å›ºé†‡
- æ³¨æ„ä½¿ç”¨éƒ¨ä½ï¼ˆè‡‰éƒ¨ã€çšºè¤¶è™•æ‡‰é¿å…ä½¿ç”¨é«˜æ•ˆåƒ¹é¡å›ºé†‡ï¼‰
- ç›£æ¸¬é•·æœŸä½¿ç”¨çš„å±€éƒ¨å‰¯ä½œç”¨

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Durvalumab]({{ "/drugs/durvalumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Human Immunoglobulin G]({{ "/drugs/human_immunoglobulin_g/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Alfacalcidol]({{ "/drugs/alfacalcidol/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Acitretin]({{ "/drugs/acitretin/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Interferon Beta-1B]({{ "/drugs/interferon_beta-1b/" | relative_url }}) - è­‰æ“šç­‰ç´š L3

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Amcinonideè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/amcinonide/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_amcinonide,
  title = {Amcinonideè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/amcinonide/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
